Roche: in deal for rights to Duchenne drug
(CercleFinance.com) - Roche said on Monday it has entered a deal that gives it exclusive rights outside the United States to market an experimental drug being developed by US biotech Sarepta Therapeutics.
The drug, SRP-9001, is currently in clinical development for Duchenne muscular dystrophy, a rare degenerative disorder causing progressive muscle loss and premature death, the Swiss drugmaker said.
Under the terms of the licensing agreement, Sarepta will receive an upfront payment of 750 million dollars in cash, and 400 million dollars in equity.
In addition, Sarepta is eligible to receive regulatory and sales milestones, and royalties on net sales.
Roche and Sarepta plan to equally share development expenses.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The drug, SRP-9001, is currently in clinical development for Duchenne muscular dystrophy, a rare degenerative disorder causing progressive muscle loss and premature death, the Swiss drugmaker said.
Under the terms of the licensing agreement, Sarepta will receive an upfront payment of 750 million dollars in cash, and 400 million dollars in equity.
In addition, Sarepta is eligible to receive regulatory and sales milestones, and royalties on net sales.
Roche and Sarepta plan to equally share development expenses.
Copyright (c) 2019 CercleFinance.com. All rights reserved.